Latest Archer Materials (ASX:AXE) News

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

Archer Materials has made significant strides in its quantum computing and medical diagnostics programs, including improved carbon qubit readout and clinical-standard silicon biochips, while securing key partnerships and maintaining a strong cash position.

Archer Materials has demonstrated electrical control in its quantum devices, marking a crucial step toward reliable qubit readout and scalable quantum chip manufacturing.

Archer Materials has partnered with CSIRO to develop cutting-edge quantum machine learning models aimed at revolutionizing fraud detection in financial transactions.

Archer Materials has successfully demonstrated that its blood potassium Biochip can be fabricated on a silicon platform, matching clinical accuracy standards and accelerating its path to commercialisation.

Archer Materials has made significant strides in quantum computing and biochip development, enhancing qubit functionality and potassium ion testing accuracy. A new partnership with IMEC aims to accelerate biochip commercialization, supported by a robust $11.6 million cash position.

Archer Materials has entered a strategic collaboration with Emergence Quantum to fast-track the development of graphene-based quantum devices, aiming to bridge cutting-edge science with commercial applications.

Archer Materials has achieved critical milestones in its carbon-based quantum technology, including wafer-scale synthesis and reproducible device performance, setting the stage for operational qubits by mid-2026.

Archer Materials has made notable advances in its quantum computing and biosensor technologies during FY25, alongside leadership changes and a widened net loss. The company’s progress signals growing momentum in its commercialisation efforts.

Archer Materials has partnered with Belgium’s IMEC to develop a scalable, cost-effective potassium ion biosensor using silicon semiconductor technology, aiming to accelerate commercial production by late 2025.

Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.

Archer Materials has successfully demonstrated its tunnel magnetoresistance (TMR) sensors operating at cryogenic temperatures, marking a key advance for quantum computing and advanced sensing applications.